ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA EditingGlobeNewsWire • 03/14/23
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022GlobeNewsWire • 11/14/22
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology ProgramsGlobeNewsWire • 08/11/22
ProQR Announces Annual General Meeting of Shareholders and Provides Leadership UpdatesGlobeNewsWire • 06/01/22
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022GlobeNewsWire • 05/09/22
Bears are Losing Control Over ProQR (PRQR), Here's Why It's a 'Buy' NowZacks Investment Research • 05/03/22
ProQR (PRQR) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/28/22
ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022GlobeNewsWire • 04/26/22
ProQR Therapeutics Pulls Plug On Inherited Retinal Disease Programs, Cuts 30% WorkforceBenzinga • 04/13/22